CytRx Corporation to Receive FDA Correspondence Regarding Clinical Development of Arimoclomol in ALS

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it will receive a written correspondence from the U.S. Food and Drug Administration (FDA) regarding its clinical program with arimoclomol as a treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

Back to news